Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $75

Benzinga · 1d ago
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $65 to $75.